

**TARGETED THERAPY IN MS: SHOULD WE AIM AT B OR T LYMPHOCYTES? –
THERAPY SHOULD BE TARGETED AGAINST T CELLS**

Olaf Stuve

USA

Multiple sclerosis (MS) is the most common inflammatory disorder of the central nervous system with an assumed autoimmune pathogenesis. Traditionally, MS has been considered a CD4⁺ T cell-mediated disease. However, several observations in the 1980s and 1990s called into question the pathogenic role of T helper cells in MS.

Recent discoveries on T cell subsets and cytokine networks have broadened our understanding of their role in autoimmunity. They also will play a major role in drug development for MS. The role of specific T cell subsets in different compartments during different disease stages will be discussed in this presentation.